

09 May 2024

## Usage of biologic and biosimilar products within rheumatology

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- **Abatacept [Orencia]** IV 51, subcut 224
- **Adalimumab [Humira]** 411
- **Adalimumab Biosimilars Imraldi** 551, Amgevita 265
- **Apremilast [Otezla]** 26
- **Baricitinib [Olumiant]** 38
- **Bimekizumab [Bimzelx]** 13
- **Certolizumab [Cimzia]** 145
- **Etanercept [Enbrel]** 117
- **Etanercept Biosimilars** 349
- **Filgotinib [Jyseleca]** <5
- **Golimumab [Simponi]** 97
- **Guselkumab [Tremfya]** <5
- **Infliximab [Remicade]** 59
- **Infliximab Biosimilars** 59 IV, <5 Subcut
- **Ixekizumab [Taltz]** 102
- **Risankizumab [Skyrizi]** <5
- **Rituximab [MabThera]** 76
- **Rituximab Biosimilars** - 163
- **Sarilumab [Kevzara]** – <5
- **Secukinumab [Cosentyx]** 242
- **Tocilizumab [Ro Actemra]** IV 46, subcut 147

09 May 2024

- **Tocilizumab Biosimilars** - <5
- **Tofacitinib [Xeljanz]** 26
- **Upadacitinib [Rinvoq]** 87
- **Ustekinumab [Stelara]** 14

**Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:**

- **Abatacept [Orencia]** <5
- **Adalimumab [Humira]** 135
- **Adalimumab Biosimilars** – 168 Imraldi, 72 Amgevita
- **Apremilast [Otezla]** 20
- **Bimekizumab [Bimzelx]** 9
- **Certolizumab [Cimzia]** 57
- **Etanercept [Enbrel]** 25
- **Etanercept Biosimilars** 107
- **Golimumab [Simponi]** 49
- **Guselkumab [Tremfya]** 4
- **Infliximab [Remicade]** 15
- **Infliximab Biosimilars** 12
- **Ixekizumab [Taltz]** 73
- **Risankizumab [Skyrizi]** <5
- **Secukinumab [Cosentyx]** 154
- **Tofacitinib [Xeljanz]** 5
- **Upadacitinib [Rinvoq]** 15
- **Ustekinumab [Stelara]** 8

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.